Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis
Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis
复制标题
DOI：
10.1183/09031936.01.17407120
复制
发表时间：
2001-04-01
影响因子：
24.3
通讯作者：
Elborn, S
中科院分区：
文献类型：
--
作者：
Bradley, J;McAlister, O;Elborn, S
这项研究的目的是确定治疗引起的运动能力和生活质量(QOL)的变化与肺功能的肺活量测量和其他疾病损害测量的相关程度。在静脉注射抗生素治疗的开始和结束时，获得疾病损害、残疾和生活质量的测量。静脉内抗生素治疗导致疾病损害、残疾和残疾的所有测量显著改善。治疗引起的运动能力变化的唯一显著预测因子是C-反应蛋白(CRP)，这解释了运动能力变化的28%。在QOL的情况下，TNO预测因素(运动量和排气量的变化)对QOL的变化有显著贡献，共同解释了QOL变化的54%。肺功能提供了一个有限的治疗结果指数。运动能力和生活质量评估有可能对囊性纤维化治疗选择的决策过程做出重大贡献，如果需要对治疗效果进行全面评估，则应直接进行测量。
The aim of the study was to determine the extent to which treatment induced changes in exercise capacity and quality of life (QoL) are related to spirometric measures of lung function and other measures of disease impairment.Twenty patients admitted to hospital with an exacerbation of pulmonary disease were recruited. Measures of disease impairment, disability and QoL were obtained at the beginning and end of an intravenous course of antibiotic therapy.Intravenous antibiotic treatment resulted in a significant improvement in all measures of disease impairment, disability and handicap. The only significant predictor of treatment induced change in exercise capacity was C-reactive protein (CRP) and this explained 28% of the variance in change in exercise capacity. In the case of QoL, tno predictors (change in exercise capacity and sputum output) contributed significantly to the change in QoL and collectively explained 54% of the variance in QoL.Lung function provides a limited index of treatment outcome. Exercise capacity and quality of life assessment have the potential to make a significant contribution to the decision making process regarding treatment choices in cystic fibrosis and should be measured directly if a comprehensive evaluation of the effect of treatment is required.